Identify and validate novel therapeutics, targets and pathways for selective tumor targeting and where possible advancing these into clinical trials. Research focus includes:

Scientific Accomplishments

Drs. Matherly and Polin have developed potent novel tumor-targeted cytotoxic agents based on the folate platform with selective membrane transport by the proton-coupled folate transporter (PCFT) and folate receptor (FR) α over the ubiquitously expressed reduced folate carrier. PCFT and FRα are highly expressed in tumors and provide means of selective tumor targeting. Studies in clinically relevant tumor cell models confirmed antitumor effects and in vivo efficacies were demonstrated with FRα- and PCFT- expressing human ovarian and mesothelioma xenografts in SCID mice. Plans are to progress these novel agents to clinical trials.

  • Lead researcher: Dr. Matherly
  • Collaborative researcher: Dr. Polin

Drs. Mohammad and Philip identified rationally designed nuclear transport inhibitors for treating pancreatic cancer. Their focus is on chromosome maintenance protein 1 (CRM1), a ubiquitous transport receptor that controls the nuclear export of key tumor suppressor and growth regulatory proteins. Over-expression of CRM1 is frequent in pancreatic cancer and is associated with increased histological grade, tumor size, metastasis and decreased survival. Based on promising preclinical results in pancreatic cancer cell lines and non-transformed human pancreatic ductal epithelial cells, patients are being enrolled on a phase I/IIb investigator-initiated clinical trial with the lead compound of this series.

  • Lead Researchers: Drs. Mohammad and Philip
  • Collaborative researchers: Drs. Heath, Mahaseth, Mohammad, Philip, Shields, Vaishampayan, and Harper

Investigation of ELK1 as a regulator of androgen receptor growth signaling receptors in prostate cancer. Researchers found that ELK1 directs a selective and sustained induction of genes that are critical for growth signaling by androgen receptor in prostate cancer cells. Studies are exploring whether disrupting the ELK1-androgen receptor interaction is possible and whether drugs can be developed for this purpose. With Dr. Heath, Dr. Ratnam is extending these studies to patients with the goal of an investigator-initiated clinical trial targeting the ELK1-AR interaction in prostate cancer patients.

  • Lead Researcher: Dr. Ratnam
  • Collaborative Researcher: Dr. Heath

The Latest From Karmanos Cancer Institute

News

IN THE NEWS – Pancreatic Cancer: Cigarette Smoke May Fuel Tumor Growth and Spread

Healthline Though it's known that smoking can cause cancer, and not just lung cancer, researchers have published a new study revealing chemicals f...

Read More

Wayne State University Celebrates Groundbreaking for $200 Million Health Sciences Research Building, Will House Oncology Research Space for Karmanos Scientists

Wayne State University (WSU) marked a major milestone in its mission to advance health and scientific discovery with the groundbreaking of the Hea...

Read More

Research and Breakthroughs: Community Conversations on Cancer Delivers Collaborative Dialogue with Community on Latest Cancer Treatments

The Barbara Ann Karmanos Cancer Institute’s Office of Community Outreach and Engagement (COE) has continued its Community Conversations on Cancer ...

Read More
News

105.9 KISS FM | Getting a Second Opinion at Karmanos

Listen Now

WJR | Karmanos Cancer Institute Continues Its Community Education Series

Listen Now

WXYT 97.1 The Ticket | ‘Get a Mammogram’

Listen Now